June 2016, Vol 7, No 5

Tyrosine kinase inhibitors (TKIs) are the mainstay of therapy for patients with epidermal growth factor receptor (EGFR) mutation–positive non–small-cell lung cancer (NSCLC), according to the updated National Comprehensive Cancer Network (NCCN) NSCLC guideline. The NCCN guideline recommends EGFR testing as part of a broad molecular profiling in patients with NSCLC.
Read Article

A “liquid biopsy” was able to detect 2 mutations in the ESR1 gene that predicted worse overall survival (OS) in women with estrogen receptor (ER)-positive metastatic breast cancer who were originally enrolled in the phase 3 BOLERO-2 clinical trial, according to results presented at the 2015 San Antonio Breast Cancer Symposium.
Read Article




Women with clinicopathologic high-risk breast cancer had nearly a 50% reduction in prescription chemotherapy, with no increased risk for metastatic recurrence when a cancer gene-based assay was used to guide treatment decision-­making, according to new data presented at the 2016 American Association for Cancer Research meeting.
Read Article





Page 2 of 3